Imetelstat Active in Myeloproliferative Disorders

Essential thrombocythemia, myelofibrosis respond to telomere targeting

Drug Active in Myeloproliferative DisordersTreatment with a drug that targets the chromosome-lengthening enzyme telomerase led to hematologic responses in all treated patients with essential thrombocythemia, a preliminary clinical trial showed.

In 16 of 18 cases, patients achieved complete hematologic responses with imetelstat. Additionally, seven of eight patients with Janus kinase 2 (JAK2) V617F mutations had molecular responses, and mutant allele burdens were reduced by as much as 66%.

Most adverse events were mild or moderate, and grade ≥3 neutropenia occurred in four of the 18 patients. All 18 patients had at least one abnormal liver-function test, as reported online in the New England Journal of Medicine.

“Imetelstat … had a clinically significant effect on disease burden in patients with essential thrombocythemia who had not had a response to previous treatment or who had had unacceptable side effects from conventional therapies,” Gabriela M. Baerlocher, MD, of University Hospital of Bern in Switzerland, and co-authors wrote in conclusion.

Click on the Source below for the complete article

Source: Drug Active in Myeloproliferative Disorders | Medpage Today

About David Wallace

Founder of PV Reporter, a resource for Myeloproliferative Neoplasm (MPN) patients and caregivers. After being diagnosed with Polycythemia Vera (PV) in 2009, I utilized social media to connect with "informed patients" and develop a better understanding of emerging treatment options. My philosophy on patient care is straight forward - "educating the patient is essential, so the patient can guide their physician to meet his or her needs." PV Reporter is a comprehensive resource hub giving visitors vital tools to become "empowered patients."

error: Content is protected !